| Literature DB >> 27611233 |
Philip A Thompson1, Vincent Lévy2, Constantine S Tam3, Chadi Al Nawakil2, François-Xavier Goudot4, Anne Quinquenel5, Loic Ysebaert6, Anne-Sophie Michallet7, Marie-Sarah Dilhuydy8, Eric Van Den Neste9, Jehan Dupuis10, Michael J Keating1, Christophe Meune4, Florence Cymbalista11.
Abstract
Atrial fibrillation (AF) occurs in 5-9% of patients treated with ibrutinib for chronic lymphocytic leukaemia (CLL); the clinical consequences and optimal management are unclear. We retrospectively studied 56 CLL patients who received ibrutinib and developed AF. Median time to onset was 3·8 months. AF was persistent in 35/56 (62%) cases despite treatment. Clinical consequences included: three episodes of severe cardiac failure (one fatal) and one stroke; eight non-thrombocytopenic patients (14%) experienced severe bleeding adverse events. Altogether, ibrutinib was permanently discontinued in 26/56 cases (46%). Data to guide optimal management are lacking and clinical practice guidelines are urgently needed.Entities:
Keywords: atrial fibrillation; chronic lymphocytic leukaemia; ibrutinib
Mesh：
Substances：
Year: 2016 PMID： 27611233 DOI： 10.1111/bjh.14324
Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998